EUVIMEDEUVIMED entdecken
Multizentrische Studie

Real‐world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti‐ TNF agent

Anthony Buisson iD, Maria Nachury, Thomas Guilmoteau, Romain Altwegg iD, Xavier Treton, Mathurin Fumery iD, Melanie Serrero, Eloïse Leclerc, Ludovic Caillo, Bruno Pereira, Aurélien Amiot iD, Guillaume Bouguen iD

Alimentary Pharmacology & Therapeutics · 2023-03 · 57 (6) · 676-688

DOI: 10.1111/apt.17305 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 19.11.2022. Verfasst von Anthony Buisson und 11 weiteren Autor:innen. Beteiligte Einrichtung: Université Clermont Auvergne, Inserm, 3iHP, CHU Clermont-Ferrand, Service d'Hépato-Gastroentérologie, Clermont-Ferrand, France. Hauptthemen laut MEDLINE: Colitis, Ulcerative. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Data comparing tofacitinib and vedolizumab in ulcerative colitis (UC) are lacking.

Aims

To compare the effectiveness of tofacitinib and vedolizumab in patients with UC who had prior exposure to anti‐TNF therapy Methods In this multicentre study, we included consecutive patients with UC ≥18 years old with partial Mayo score >2 and prior anti‐TNF exposure, who started tofacitinib or vedolizumab between January 2019 and June 2021. Comparisons were performed using propensity score analyses (inverse probability of treatment weighting).

Results

Overall, 126 and 178 patients received tofacitinib and vedolizumab, respectively. Intensified induction (vedolizumab infusion at week 10 or tofacitinib 10 mg b.d until week 16) was performed in 28.5% and 41.5% of patients, respectively. After propensity‐score analysis, corticosteroid‐free clinical remission (partial Mayo score ≤2) was achieved at week 16 in 45.1% and 40.2% of patients receiving tofacitinib and vedolizumab, respectively (aOR = 0.82 [0.35–1.91], p = 0.64). Endoscopic improvement (corticosteroid‐free clinical remission and endoscopic Mayo score ≤1) (aOR = 0.23[0.08–0.65], p = 0.0032) and histological healing (endoscopic improvement + Nancy histological index ≤1) (13.4% vs 3.2%, aOR = 0.21[0.05–0.91], p = 0.023) were higher at week 16 in patients treated with tofacitinib. No factor was predictive of tofacitinib effectiveness. At least one primary failure to a biologic (OR = 0.46[0.22–0.99], p = 0.049), partial Mayo score >6 (OR = 0.39[0.17–0.90], p = 0.029) and CRP level > 30 mg/L at baseline (OR = 0.08[0.01–0.85], p = 0.036) were associated with vedolizumab failure.

Conclusion

Tofacitinib and vedolizumab are effective in UC after failure of anti‐TNF agents. However, tofacitinib seems more effective, especially in severe disease and primary failure to biologics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeHumansAdolescentTumor Necrosis Factor InhibitorsAntibodies, Monoclonal, HumanizedTreatment OutcomeRemission InductionGastrointestinal AgentsPiperidinesPyrimidines

Substanzen

Tumor Necrosis Factor InhibitorsAntibodies, Monoclonal, HumanizedGastrointestinal AgentsvedolizumabtofacitinibPiperidinesPyrimidines

Autor:innen und Institutionen

  • Université Clermont Auvergne, Inserm, 3iHP, CHU Clermont-Ferrand, Service d'Hépato-Gastroentérologie, Clermont-Ferrand, France.
  • Université Clermont Auvergne, Inserm U1071, M2iSH, USC-INRA 2018, Clermont-Ferrand, France.
  • Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France.
  • Department of Hepatogastroenterology, CHU St Eloi Montpellier, Montpellier, France.
  • Gastroenterology Department, Beaujon Hospital, Assitance Publique-Hôpitaux de Paris (AP-HP), Clichy, France.
  • CHU Amiens, Université de Picardie Jules Verne, Unité Peritox, France.

ORCID-Profile: Anthony Buisson, Romain Altwegg, Mathurin Fumery, Aurélien Amiot, Guillaume Bouguen

Förderung

  • Pfizer

Zitieren

APA

Buisson, A., Nachury, M., Guilmoteau, T., Altwegg, R., Treton, X., Fumery, M., Serrero, M., Leclerc, E., Caillo, L., Pereira, B., Amiot, A., & Bouguen, G. (2023). Real‐world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti‐ TNF agent. Alimentary Pharmacology & Therapeutics, 57(6), 676-688. https://doi.org/10.1111/apt.17305

Vancouver

Buisson A, Nachury M, Guilmoteau T, Altwegg R, Treton X, Fumery M, et al. Real‐world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti‐ TNF agent. Alimentary Pharmacology & Therapeutics. 2023;57(6):676-688. doi:10.1111/apt.17305

BibTeX
@article{Buisson2023,
  author = {Buisson, Anthony and Nachury, Maria and Guilmoteau, Thomas and Altwegg, Romain and Treton, Xavier and Fumery, Mathurin and Serrero, Melanie and Leclerc, Eloïse and Caillo, Ludovic and Pereira, Bruno and Amiot, Aurélien and Bouguen, Guillaume},
  title = {Real‐world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti‐ TNF agent},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2023},
  volume = {57},
  number = {6},
  pages = {676--688},
  doi = {10.1111/apt.17305}
}
Kostenlos starten →